IDRI Publication List **updated 6/10/2008**
In chronological order by disease topic

Leishmania

1. Skeiky, Y.A.W., Benson, D.R., Elwasila, M., Badaro, R., Burns, J.M., and Reed, S.G. 1994. Shared antigens between *Leishmania* and *Trypanosoma cruzi*: characterization of the *Leishmania chagasi* acidic ribosomal protein PO. **Infect. and Immun.** 62:1643-1651.
2. Skeiky, Y.A.W., J.A. Guderian, D.R. Benson, O. Bacelar, E.M. Carvalho, M. Kubin, R. Badaro, G. Trinchieri, and S.G. Reed. 1995. A recombinant *Leishmania* antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin-12. **J. Exp. Med.** 181:1527-1537.
3. Ghalib, H.W., J.A. Whittle, M. Kubin, F.A. Hashim, A.M. El-Hassan, K.H. Grabstein, G. Trinchieri, and S.G. Reed. 1995. IL-12 enhances Th1 type responses in human *Leishmania donovani* infections. **J. Immunol.** 154:4623-4629.
4. Cunha, S., M. Freire, C. Eulalio, J. Critosvao, E. Netto, W.D. Johnson, Jr., S.G. Reed, and R. Badaro. 1995. Visceral leishmaniasis in a new ecological niche near a major metropolitan area of Brazil. **Trans. Roy. Soc. Trop. Med. Hyg.** 89:155-158.
5. Dillon, D.C., C.H. Day, J.A. Whittle, A.J. Magill, and S.G. Reed. 1995. Characterization of a *Leishmania tropica* antigen that detects immune responses in Desert Storm viscerotropic leishmaniasis patients. **Proc. Nat. Acad. Sci. USA** 92:7981-7985.
6. Skeiky, Y.A.W., D.R. Benson, J.A. Guderian, J.A. Whittle, O. Bacelar, E.M. Carvalho, and S.R. Reed. 1995. Immune responses of leishmaniasis patients to *Leishmania* and human heat shock proteins. **Infect. and Immun.** 63:4105-4114.
7. Campos-Neto, A., L. Soong, J.L. Cordova, D. Sant'Angelo, Y.A.W. Skeiky, N.H. Ruddle, S.G. Reed, C. Janeway, Jr., and D. McMahon-Pratt. 1995. Cloning and expression of a *Leishmania donovani* gene instructed by a peptide isolated from major histocompatibility complex class II molecules of infected macrophages. **J. Exp. Med.** 182:1423-1433.
8. Singh, S., A. Gilman-Sachs, K.-P. Chang and S.G. Reed. 1995. Diagnostic and prognostic value of rK39 antigen in Indian leishmaniasis. **J. Parasitol.** 81:1000-1003.
9. Badaro, R., D.R. Benson, M. C. Eulalio, M. Freire, S. Cunha, E.M. Netto, D. Pedral-Sampaio, C. Madureira, J.M. Burns, Jr., J.R. David, and S.G. Reed. 1996. rK39: A cloned antigen of *Leishmania chagasi* that both detects and predicts active visceral leishmaniasis. **J. Infect. Dis.** 173:758-762.
10. Campbell, K.A., P.J. Ovendale, M.K. Kennedy, W.C. Fanslow, S.G. Reed, and C.R. Maliszewski. 1996. CD40 ligand is required to generate a protective cell-mediated immune response to *Leishmania major*. **Immunity** 4:283-289.
11. Webb, J.R., D. Kaufmann, A.Campos-Neto, and S.G. Reed. 1996. Molecular cloning of a novel protein antigen of *Leishmania major* that elicits a potent immune response in experimental murine leishmaniasis. **J. Immunol.** 157:5034-5041.
12. Sundar, S., S.G. Reed, S. Sharma, A. Mehrotra, and H.W. Murray. 1997. Circulating T Helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. **Am. J. Trop. Med. Hyg.** 56:522-525.

13. Probst, P., Y.A.W. Skeiky, M. Steeves, A. Gervassi, K.H. Grabstein, and S.G. Reed. 1997. A *Leishmania* protein that modulates interleukin (IL)-12, IL-10 and tumor necrosis factor- production and expression of B7-1 in human monocyte-derived antigen-presenting cells. **Eur. J. Immunol.** 27:2634-2642.
14. Skeiky, Y.A.W., D.R. Benson, J.L.M. Costa, R. Badaro and S.G. Reed. 1997. Association of *Leishmania* heat shock protein 83 antigen and immunoglobulin G4 antibody titers in Brazilian patients with diffuse cutaneous leishmaniasis. **Infect. and Immun.** 65:5368-5370.
15. Webb, J.R., A. Campos-Neto, Y.A.W. Skeiky, and S.G. Reed. 1997. Molecular characterization of the heat-inducible LmSTI1 protein of *Leishmania major*. **Mol. Biochem. Parasitol.** 89:179-193.
16. Webb, J.R., A. Campos-Neto, P.J. Ovendale, T.I. Martin, E.J. Stromberg, R. Badaro, and S.G. Reed. 1998. Human and murine immune responses to a novel *Leishmania major* recombinant protein encoded by a multi-copy gene family. **Infect. and Immun.** 66:3279-3289.
17. Ozensoy, S., Y. Ozbel, N. Turgay, M. Ziya Alkan, K. Gul, A. Gilman-Sachs, K.-P. Chang, S.G. Reed, and M. Ali Ozcel. 1998. Serodiagnosis and epidemiology of visceral leishmaniasis in Turkey. **Am. J. Trop. Med. Hyg.** 59:363-369.
18. Skeiky, Y.A.W., M. Kennedy, D. Kaufman, M.M. Borges, J.A. Guderian, J.K. Scholler, P.J. Ovendale, K.S. Picha, P.J. Morrissey, K.H. Grabstein, A. Campos-Neto, and S.G. Reed. 1998. LeIF: A recombinant *Leishmania* protein that induces an IL-12 mediated Th1 cytokine profile. **J. Immunol.** 161:6171-6179.
19. Bhatia, A., N.S. Daifalla, S. Jen, R. Badaro, S.G. Reed, and Y.A.W. Skeiky. 1999. Cloning, characterization and serological evaluation of K9 and K26: two related hydrophilic antigens of *Leishmania chagasi*. **Mol. Biochem. Parasitol** 102:249-261.
20. Medeiros, I.M., S.G. Reed, A. Castelo, and R. Salomao. 2000. Circulating levels of sTNFR and discrepancy between cytotoxicity and immnoreactivity of TNF-α in patients with visceral leishmaniasis. **Clin. Microbiol. Infect.** 6:34-37.
21. Reed S.G.. 2001. Leishmaniasis vaccination: targeting the source of infection. **J. Exp Med.** 194:F7-F9.
22. Probst, P., E. Stromberg, H.W. Ghalib, M. Mozel, R. Badaro, S.G. Reed, and J.R. Webb. 2001. Identification and characterizatio of T cell stimulating antigens from Leishmania by CD4 T cell expression cloning. **J. Immunol.** 166:498-505.
23. Mendez, S., S. Gurunathan, S. Kamhawi, Y. Belkaid, M.A. Moga, Y.A.W. Skeiky, A. Campos-Neto, S.G. Reed, R.A. Seder and D. Sacks. 2001. The potency and durability of dna- and protein-based vaccines against *Leishmania major* evaluated using low-dose, intradermal challenge. **J. Immunol.** 166:5122-5128.
24. Campos-Neto, A., R. Porrozzi, K. Greeson, R.N. Coler, J.R. Webb, Y.A.W. Skeiky, S.G. Reed, and G. Grimaldi, Jr. 2001. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of human disease. **Infect. and Immun.** 69:4103-4108
25. Borges, M.M., A. Campos-Neto, P. Sleath, K.H. Grabstein, P.J. Morrissey, Y.A.W. Skeiky, and S.G. Reed. 2001. Potent Stimulation of the innate immune system by a *Leishmania brasiliensis* recombinant protein. **Infect. Immun.** 69:5270-5277.
26. Campos-Neto, A., J.R. Webb, K. Greeson, R.N. Coler, Y.A.W. Skeiky, and S.G. Reed. 2002. Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial

fusion proteins confers protection against *Leishmania major* infection in susceptible BALB/c mice. **Infect. and Immun.** 70:2828-2836.

27. Coler, R.N., Y.A. Skeiky, K. Bernards, K. Greeson, D. Carter, C. Cornellison, F. Modabber, A. Campos-Neto, and S.G. Reed. 2002. Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, *Leishmania major* stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. **Infect. Immun.** 70:4215-4225.
28. Skeiky, Y.A.W., R.N. Coler, M. Brannon, E. Stromberg, K. Greeson, R.T. Crane, A. Campos-Neto, and S.G. Reed. 2002. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL® adjuvant. **Vaccine**. 20(27-28):3292.
29. Braz, R.F.S., E.T. Nascimento, D.R.A. Martins, M.E. Wilson, R.D. Pearson, S.G. Reed, and S.M.B. Jeronimo. 2002. The sensitivity and specificity of *Leishmania chagasi* recombinant k39 antigen in the diagnosis of American visceral leishmaniasis and in differentiating active from subclinical infection. **Am. Journ. Trop. Med. Hyg.** 67:344-348.
30. Zerpa, O., M. Ulrich, M. Benitez, C. Avila, V. Rodriguez, M. Centeno, D. Belizario, S.G. Reed, and J. Convit. 2002. Epidemiological and immunological aspects of human visceral leishmaniasis on Margarita Island, Venezuela. **Mem. Inst. Oswaldo Cruz** 97:1079-1083.
31. Chang, K.P., S.G. Reed, B.S. McGwire, and L. Soong. 2003. Leishmania model for microbial virulence: the relevance of parasite multiplication and pathoantigenicity. **Acta Trop.** 85:375-390.
32. Reed, S.G., R.N. Coler, and A. Campos-Neto. 2003. Development of a leishmaniasis vaccine: the importance of MPL. **Expert Rev. Vaccines** 2:239-252.
33. Coler, R.N., and S.G. Reed. 2005. Second-generation vaccines against leishmaniasis. **Trends Parasitol**. May; 21 (5):244-249.
34. Fujiwara, R.T., A.M. Vale, J.C. França da Silva, R.T. da Costa, J.D.S. Quetz, O.A. Martins Filho, A.B. Reis, R. Corrêa Oliveira, G.L. Machado-Coelho, L.L. Bueno, J.M. Bethony, G. Frank, E. Nascimento, O. Genaro, W. Mayrink, S. Reed, and A. Campos-Neto. 2005. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis. **Vet. Res.** 36:827–838.
35. Goto Y, Coler RN, Reed SG. Bioinformatic identification of tandem repeat antigens of the Leishmania donovani complex. Infect Immun. 2007 Feb;75(2):846-51. Epub 2006 Nov 6.
36. Goto, Y, R.N. Coler, J. Guderian, R. Mohamath, and S.G. Reed. 2006. Cloning, characterization, and serodiagnostic evaluation of *Leishmania infantum* tandem repeat proteins. **Infect. Immun.** July; 74(7):3939-3945.
37. Badaro, R., I. Lobo, A. Munõs, E.M. Netto, F. Modabber, A. Campos-Neto, R.N. Coler and S.G. Reed. 2006. Immunotherapy for Drug Refractory Mucosal Leishmaniasis. **J. Inf. Dis.** 194:1151-1159.
38. Goto, Y., R.N. Coler, and S.G. Reed. 2007. Bioinformatic identification of tandem repeat antigens of the *Leishmania donovani* complex. **Infect. Immun.** 75:846-851.
39. Darrah, P.A., D.T. Patel, P.M. De Luca, R.W. Lindsay, D.F. Davey, B.J. Flynn, S.T. Hoff, P. Andersen, S.G. Reed, S.L. Morris, M. Roederer, and R.A. Seder. 2007. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against *Leishmania major*. **Nat. Med.** 13:843-850.
40. Coler, R.N., Y. Goto, L. Bogatzki, V. Raman, and S.G. Reed. 2007. Leish-111f, a recombinant polyprotein vaccine that protects against visceral leishmaniasis by elicitation of CD4+ T cells. **Infect. Immun.** 75:4648-4654.

41. Goto, Y., L.Y. Bogatzki, S. Bertholet, R.N. Coler, and S.G. Reed. 2007. Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant. **Vaccine**. 25:7450-7458.
42. Miret, J., E. Nascimento, W. Sampaio, J.C. Franca, R.T. Fujiwara, A. Vale, E. Santos Dias, E. Vieira, R. T. da Costa, W. Mayrink, A. Campos-Neto, S.G. Reed. 2008. Evaluation of an immunochemotherapeutic Q1 protocol constituted of *N*-methyl meglumine antimoniate (Glucantime®) and the recombinant Leish-110f® + MPL-SE® vaccine to treat canine visceral leishmaniasis. **Vaccine**. 2008 Mar 17;26(12):1585-94. Epub 2008 Feb 4. PMID: 18328956
43. Vedvick, T.S., Carter L., Moulton, G., Goto, Y., Bertholet, S., Reed S.G., Carter, D. 2008. An Improved manufacturing process for a recombinant polyprotein vaccine. **Biopharm International**. Supplement January, 14-22.

Leprosy

44. Reece, S.T. G. Ireton, R. Mohamath, J. Guderian, W. Goto, R. Gelber, N. Groathouse, J. Spencer, P. Brennan, and S.G. Reed. 2006. ML0405 and ML2331 are antigens of *Mycobacterium leprae* with potential for diagnosis of leprosy. **Clin. Vaccine Immunol.** March;13(3):333-340.
45. Duthie, M.S., S.T. Reece, R. Lahiri, W. Goto, V.S. Raman, J. Kaplan, G.C. Ireton, S. Bertholet, T.P. Gillis, J.L. Krahenbuhl, and S.G. Reed. 2007. Antigen-specific cellular and humoral responses are induced by intradermal *Mycobacterium leprae* infection of the mouse ear. **Infect Immun.** Nov;75(11):5290-5297.
46. Duthie, M.S., W. Goto, G.C. Ireton, S.T. Reece, L.P. Cardoso, C.M. Martelli, M.M. Stefani, M. Nakatani, R.C. de Jesus, E.M. Netto, M.V. Balagon, E. Tan, R.H. Gelber, Y. Maeda, M. Makino, D. Hoft, and S.G. Reed. 2007. Use of protein antigens for early serological diagnosis of leprosy. **Clin Vaccine Immunol**. Nov;14(11):1400-1408.

Miscellaneous

47. Akridge, R.E., L.M. Keiko, and S.G. Reed. 1994. Interleukin-10 is induced during HIV-1 infection and is capable of decreasing viral replication in human macrophages. **J. Immunol.** 153:5782-5789.
48. Akridge, R.E., and S.G. Reed. 1996. Interleukin-12 decreases HIV-1 replication in human macrophages reconstituted with autologous PBMC. **J. Infect. Dis.** 173:559-564.
49. Lewinsohn, D.M., T. Tough-Bement, D.H. Lynch, K.H. Grabstein, S.G. Reed, and M.R. Alderson. 1998. Human purified protein derivative-specific CD4+ T cells utilize both CD95-dependent and CD95-independent cytolytic mechanisms. **J. Immunol.** 160:2374-2379.
50. Persing, D.H., R.N. Coler, M.J. Lacy, D.A. Johnson, J.R. Baldridge, R.M. Hershberg, and S.G. Reed. 2002. Taking toll: lipid A mimetics as adjuvants and immunomodulators. **Trends Microbiol.** 10:S32-S37.
51. Reed, S.G. 1993. Macrophage activation and inactivation in protozoal infections. In: **Hemopoietic Growth Factors and Mononuclear Phagocytes**, R. van Furth, editor, Basel, Karger, pp 98-110.
52. Reed, S.G., and A. Campos-Neto. 2003. Vaccines for parasitic and bacterial diseases. In: **Current Opininions in Immunology** 15:456-460.
53. Fox, C.B., R.C. Anderson, T.S. Dutill, Y. Goto, S.G. Reed, and T.S. Vedvick. 2008. Monitoring the effects of component structure and source on formulation

stability and adjuvant activity of oil-in-water emulsions. **Colloids and Surfaces B: Biointerfaces** 65:98–105. PMID: 18440205

Trypansoma Cruzi

54. Skeiky, Y.A.W., Benson, D.R., Elwasila, M., Badaro, R., Burns, J.M., and Reed, S.G. 1994. Shared antigens between *Leishmania* and *Trypanosoma cruzi*: characterization of the *Leishmania chagasi* acidic ribosomal protein PO. **Infect. and Immun.** 62:1643-1651.
55. Reed, S.G., C.E. Brownell, D.M. Russo, J.S. Silva, K.H. Grabstein, and P.J. Morrissey. 1994. Interleukin-10 mediates susceptibility to *Trypanosoma cruzi* infection. **J. Immunol.** 153:3135-3140.
56. Cardillo, F., J.C. Voltarelli, S.G. Reed, and J.S. Silva. 1996. Regulation of *Trypanosoma cruzi* infection in mice by gamma interferon and interleukin-10: Role of NK cells. **Infect. and Immun.** 64:128-134.
57. Ismail, S.O., W. Paramchuk, Y.A.W. Skeiky, S.G. Reed, A. Bhatia, and L. Gedamu. 1997. Molecular cloning and characterization of two iron superoxide dismutase cDNAs from *Trypanosoma cruzi*. **Mol. Biochem. Parasitol.** 86:187-197.
58. Reed, S.G. 1998. Immunology of *Trypanosoma cruzi* infections. In: **Chemical Immunology, Immunology of Intracellular Parasitism**. 70:124-143.
59. Duthie MS, Kahn SJ. Treatment with alpha-galactosylceramide before Trypanosoma cruzi infection provides protection or induces failure to thrive. **J Immunol**. 2002 Jun 1;168(11):5778-85. PMID: 12023379
60. Ferreira, A.W., Z.R. Belem, E.A. Lemos, S.G. Reed, and A. Campos-Neto. 2001. LemEnzyme-linked immunosorbent assay for serological diagnosis of Chagas' Disease employing a Trypanosoma cruzi recombinant antigen that consists of four different peptides. **J. Clin. Microbiol**. 39:4390-4395.
61. Campos-Neto, A, I. Suffia, K.A. Cavassani, S. Jen, K. Greeson, P. Ovendale, J.S. Silva, **S.G. Reed**, and Y.A. Skeiky. 2003. Cloning and characterization of a gene encoding an immunoglobulin-binding receptor on the cell surface of some members of the family trypanosomatidae. **Infect. Immun.** 71:5065-5076.
62. Duthie MS, Kahn M, White M, Kapur RP, Kahn SJ. Critical proinflammatory and anti-inflammatory functions of different subsets of CD1d-restricted natural killer T cells during Trypanosoma cruzi infection. **Infect Immun**. 2005 Jan;73(1):181-92.PMID: 15618153
63. Duthie MS, Cetron MS, Van Voorhis WC, Kahn SJ. Trypanosoma cruzi-infected individuals demonstrate varied antibody responses to a panel of trans-sialidase proteins encoded by SA85-1 genes. **Acta Trop**. 2005 Mar;93(3):317-29. PMID: 15725381
64. Duthie MS, Kahn M, White M, Kapur RP, Kahn SJ. Both CD1d antigen presentation and interleukin-12 are required to activate natural killer T cells during Trypanosoma cruzi infection. **Infect Immun**. 2005 Mar;73(3):1890-4. PMID: 15731095
65. Duthie MS, Kahn SJ. NK cell activation and protection occur independently of natural killer T cells during Trypanosoma cruzi infection. Int Immunol. 2005 May;17(5):607-13. Epub 2005 Mar 31. PMID: 15802307

66. Duthie MS, Kahn SJ. During acute Trypanosoma cruzi infection highly susceptible mice deficient in natural killer cells are protected by a single alpha-galactosylceramide treatment. **Immunology**. 2006 Nov;119(3):355-61. Epub 2006 Jul 26. PMID: 16879622
67. Duthie MS, Kahn M, Zakayan A, White M, Kahn SJ. Parasite-induced chronic inflammation is not exacerbated by immunotherapy before or during Trypanosoma cruzi Infection. **Clin Vaccine Immunol**. 2007 Aug;14(8):1005-12. Epub 2007 May 30. PMID: 17538117

Tuberculosis

68. Lewinsohn, D.M., M.R. Alderson, A.L. Briden, S.R. Riddell, S.G. Reed, and K.H. Grabstein. 1998. Characterization of human CD8+ T cells reactive with *Mycobacterium tuberculosis*-infected antigen presenting cells. **J. Exp. Med.** 187:1633-1640.
69. Webb, J.R., T.S. Vedvick, M.R. Alderson, J.A. Guderian, P.J. Ovendale, S.M. Johnson, S.G. Reed, and Y.A.W. Skeiky. 1998. Molecular cloning, expression and immunogenicity of MTB12, a novel low molecular weight secreted antigen of *Mycobacterium tuberculosis*. **Infect. and Immun.** 66:4208-4214.
70. Coler R.N., Y.A.W. Skeiky, T. Vedvick, T. Bement, P. Ovendale, A. Campos-Neto, M.R. Alderson, and S.G. Reed. 1998. Molecular cloning and immunological reactivity of a novel low-molecular-mass antigen of *Mycobacterium tuberculosis*. **J. Immunol.** 161:2356-2364.
71. Dillon, D., M.R. Alderson, C.H. Day, D. Lewinsohn , R. Coler, T. Bement, A. Campos-Neto, Y.A.W. Skeiky, I.M. Orme, S. Steen, W. Dalemans, R. Badaro, and S.G. Reed. 1999. Molecular characterization and human T cell responses to a member of a novel *Mycobacterium tuberculosis* Mtb39 gene family. **Infect. and Immun.** 67:2941-2950.
72. Skeiky, Y.A.W., M.J. Lodes, J.A. Guderian, R. Mohamath, T. Bement, M.R. Alderson, and S.G. Reed. 1999. Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of *Mycobacterium tuberculosis*. **Infect. and Immun.** 67:3998-4007.
73. Alderson, M.R., T. Bement, C.H. Day, L. Zhu, D. Molesh, Y.A.W. Skeiky, R. Coler, D.M. Lewinsohn, S.G. Reed, and D.C. Dillon. 2000. Expression cloning of an immunodominant family of *Mycobacterium tuberculosis* antigens using human CD4+ T cells. **J. Exp. Med.** 191:551-559.
74. Skeiky, Y.A.W., P.J. Ovendale, S. Jen, M.R. Alderson, D.C. Dillon, S. Smith, C.B. Wilson, I.M. Orme, S.G. Reed, and A. Campos-Neto. 2000. T cell expression cloning of a *Mycobacterium tuberculosis* gene encoding a protective antigen associated with the early control of infection. **J. Immunol.** 165:7140-7149.
75. Hendrickson, R.C., J.F. Douglass, L.D. Reynolds, P.D. McNeill, D. Carter, S.G. Reed, and R.L. Houghton. 2000. Mass Spectrometric identification of Mtb81: a novel serological marker for tuberculosis. **J. Clin. Microbiol.** 38:2354-2361.
76. Coler, R.N., Y.A.W. Skeiky, P.J. Ovendale, T.S. Vedvick, L. Gervassi, J. Guderian, S. Jen, S.G. Reed, and A. Campos-Neto. 2000. Cloning of a *Mycobacterium tuberculosis* gene encoding a PPD protein that elicits strong tuberculosis specific delayed type hypersensitivity. **J. Infect. Dis.** 182:224-233.
77. Dillon, D.C., M.R. Alderson, C.H. Day, T. Bement, A. Campos-Neto, Y.A.W. Skeiky, T. Vedvick, R. Badaro, S.G. Reed, and R.L. Houghton. 2000. Molecular

and immunological characterization of *Mycobacterium tuberculosis* CFP-10, an immunodiagnostic antigen missing in *Mycobacterium bovis* BCG. **J. Clin. Microbiol.** 38:3285-3290.

78. Lewinsohn, D.M., A.L. Briden, S.G. Reed, K.H. Grabstein, and M.R. Alderson. 2000. *Mycobacterium tuberculosis*-reactive CD8+ T lymphocytes: the relative contribution of classical versus nonclassical HLA restriction. **J. Immunol.** 165:925-930.
79. Lewinsohn, D.M., L. Zhu, V.J. Madison, D.C. Dillon, S.P. Fling, S.G. Reed, K.H. Grabstein, and M.R. Alderson. 2001. Classically restricted human CD8(+) T lymphocytes derived from *Mycobacterium tuberculosis*-infected cells: definition of antigenic specificity**. J. Immunol.** 166:439-446.
80. Coler, R.N., A. Campos-Neto, P. Ovendale, F.H. Day, S.P. Fling, L. Zhu, N. Serbina, J.L. Flynn, S.G. Reed, and M.R. Alderson. 2001. Vaccination with the T cell antigen Mtb 8.4 protects against challenge with *Mycobacterium tuberculosis*. **J. Immunol.** 166:6227-6235.
81. Lodes, M.J., D.C. Dillon, R. Mohamath, C.H. Day, D.R. Benson, L.D. Reynolds, P. McNeill, Y.A.W. Skeiky, R. Badaro, D.H. Persing, S.G. Reed, and R.L. Houghton. 2001. Serological expression cloning and immunological evaluation of MTB48, a novel *Mycobacterium tuberculosis* antigen. **J. Clin. Microbiol.** 39:2485-2493.
82. Campos-Neto, A., V. Rodrigues-Júnior, D.B. Pedral-Sampaio, E.M. Netto, P.J. Ovendale, R.N. Coler, Y.A.W. Skeiky, R. Badaró and S.G. Reed. 2001. Evaluation of DPPD, a single recombinant *Mycobacterium tuberculosis* protein, as an alternative antigen for the Mantoux test. **Tuberculosis** 81:353-358.
83. Reed, S.G., M.R. Alderson, W. Dalemans, Y. Lobet, and Y.A. Skeiky. 2003. Prospects for a better vaccine against tuberculosis. **Tuberculosis** (Edinb).83:213-219.
84. Liu, C., E. Flamoe, H.J. Chen, D. Carter, S.G. Reed, and A. Campos-Neto. 2004. Expression and purification of immunologically reactive DPPD, a recombinant Mycobacterium tuberculosis skin test antigen, using Mycobacterium smegmatis and Escherichia coli host cells **Can. J. Microbiol.** 50:97-105.
85. Mukherjee, S., N. Daifalla, Y. Zhang, J. Douglass, L. Brooks, T. Vedvick, R. Houghton, S.G. Reed, and A. Campos-Neto. 2004. Potential serological use of a recombinant protein that is a replica of a *Mycobacterium tuberculosis* protein found in the urine of infected mice. **Clin. Diagn. Lab. Immunol.** 11:280-286.
86. Skeiky, Y.A., M.R. Alderson, P.J. Ovendale, J.A. Guderian, L. Brandt, D.C. Dillon, A. Campos-Neto, Y. Lobet, W. Dalemans, I.M. Orme, and S.G. Reed. 2004. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. **J. Immunol.** 172:7618-7628.
87. Brandt, L., Y.A. Skeiky, M.R. Alderson, Y. Lobet, W. Dalemans, O.C. Turner, R.J. Basaraba, A.A. Izzo, T.M. Lasco, P.L. Chapman, S.G. Reed, and I.M. Orme. 2004. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the *Mycobacterium tuberculosis* 72-kilodalton fusion polyprotein Mtb72F in M. *tuberculosis*-infected guinea pigs. **Infect. Immun**. 72:6622-6632.
88. Reece, S.T., N. Stride, P. Ovendale, S.G. Reed, and A. Campos-Neto. 2005. Skin test performed with highly purified *Mycobacterium tuberculosis* recombinant protein triggers tuberculin shock in infected guinea pigs. **Infect. Immun.** 73:3301-3306.
89. Skeiky, Y.A., M.R. Alderson, P.J. Ovendale, Y. Lobet, W. Dalemans, I.M. Orme, S.G. Reed, and A. Campos-Neto. 2005 Protection of mice and guinea pigs

against tuberculosis induced by immunization with a single *Mycobacterium tuberculosis* recombinant antigen, MTB41. **Vaccine** 23:3937-3745.
90. Irwin, S.M., A.A. Izzo, S.W. Dow, Y.A. Skeiky, S.G. Reed, M.R. Alderson, and I.M. Orme. 2005. Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein. **Infect. Immun.** 73:5809-5816.
91. Mukherjee S., S.S. Kashino, Y. Zhang, N. Daifalla, V. Rodrigues, Jr., S.G. Reed, and A. Campos-Neto. 2005. Cloning of the gene encoding a protective *Mycobacterium tuberculosis* secreted protein detected in vivo during the initial phases of the infectious process. **J. Immunol.** 175: 5298–5305.
92. Tsenova, L., R. Harbacheuski, A.L. Moreira, E. Ellison, W. Dalemans, M.R. Alderson, B. Mathema, S.G. Reed, Y.A. Skeiky, and G. Kaplan. 2006. Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis. **Infect. Immun.** 74:2392-2401.
93. Keeler, E., M.D. Perkins, P. Small, C. Hanson, S.G. Reed, J. Cunningham, J.E. Aledort, L. Hillborne, M.E. Rafael, F. Girosi, and C. Dye. 2006. Reducing the global burden of tuberculosis: The contribution of improved diagnostics. **Nature** Nov 23;444 Suppl 1:49-57.